Our Latest News
Find our latest news below and follow us on our social media platforms.
RxCelerate’s new company values, co-created by our people
Cambridge, UK, July 2024We are pleased to share our new company values – to support us as we continue building and developing as a people-first organisation. These values were shaped through a collaborative, company-wide initiative, where every employee was invited...
New Drosophila screening lab further expands RxCelerate’s drug discovery and development capabilities
Cambridge, UK Wednesday 24th April 2024, 9AM GMTRxCelerate is excited to launch our new fly screening service, further expanding the bespoke and flexible drug discovery and development services we offer. Cambridge, UK, 24 April 2024: The new lab offers cutting-edge...
RxCelerate a power behind many drug development thrones
Cambridge, UK – January 23, 2020 BioMed Realty (“BioMed Realty” or the “Company”), a Blackstone portfolio company and a leading provider of real estate solutions to the life sciences community, and RxCelerate, one of the leading out-sourced drug discovery and...
RxCelerate acquires Methuselah Health and launches ProQuant™ world-beating proteomics service
Cambridge, UK and Cambridge, MA Tuesday 22nd November 2022, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today announced the acquisition of drug discovery company Methuselah Health UK Ltd for an undisclosed sum....
RxCelerate launch RxNfinity™: a next-generation machine learning-enabled small molecule discovery platform
Cambridge, UK and Cambridge, MA – Tuesday 19th July 2022, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new small molecule discovery platform, RxNfinity™, that leverages machine learning,...
RxCelerate launch Galaxy™: a next-generation antibody discovery platform
Cambridge, UK and Cambridge, MA – Tuesday 16th February 2021, 1pm GMT RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Galaxy™, that offers significant advantages over...